Torrent Pharma (Results Review Q2FY22): Tepid quarter; steady outlook. Maintain ADD
The company repaid debt of INR4.9bn in H1 and is on track to reduce it by ~INR10bn in FY22. We reduce our EBITDA estimates by 4-5% for FY22-23e and...
127 Views
Torrent Pharmaceuticals: India Growth Drives Steady Numbers
A strong growth track in top brands, measured new launches (including innovative launches) besides strong balance sheet and comfort on corporate...
155 Views
HSIE Results Daily: DLF, Dr. Reddy’s, IndusInd Bank and More
HSIE Results Daily DLF: DLF surprised positively on presales at INR 10bn (6.6x/-5% YoY/QoQ) despite the lockdown during the quarter. While office...
175 Views
DF on a strong footing; making inroads in Trade Generics
TRP's 1QFY22 performance was largely in line with our estimates. Growth momentum in the Domestic Formulation (DF) business was offset by a muted...
268 Views